Shopping Cart
- Remove All
- Your shopping cart is currently empty
Anti-B7-1 Antibody-FITC (4I630) is a FITC-conjugated Mouse antibody targeting B7-1. Anti-B7-1 Antibody-FITC (4I630) can be used in FCM.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 T | $81 | 7-10 days | |
100 T | $176 | 7-10 days |
Description | Anti-B7-1 Antibody-FITC (4I630) is a FITC-conjugated Mouse antibody targeting B7-1. Anti-B7-1 Antibody-FITC (4I630) can be used in FCM. |
Alias | CD80 molecule |
Ig Type | Monoclonal Mouse IgG1 |
Clone | 4I630 |
Reactivity | Human |
Verified Activity | Profile of anti-B7-1 (CD80) reactivity on U937 cells analyzed by flow cytometry. Cells should be Fc-blocked by treatment with 20 μg of human IgG/106cells for 1 hour at 4 °C prior to staining, washed, then stained with FITC Mouse anti-B7-1 (CD80). |
Application | FCM |
Recommended Dose | 10 μl/Test, 0.1 mg/ml |
Antibody Type | Monoclonal |
Host Species | Mouse |
Construction | This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human CD80 / B7-1 (rh CD80 / B7-1; TMPY-01063; NP_005182.1; Met 1-Asn 242) and conjugated with FITC under optimum conditions, the unreacted FITC was removed. |
Purification | Protein A |
Appearance | Liquid |
Formulation | PBS solution containing 0.5% BSA and 0.03%ProClin300 |
Research Background | The B-lymphocyte activation antigen B7-1 (referred to as B7), also known as CD80, is a member of cell surface immunoglobulin superfamily and is expressed on the surface of antigen-presenting cells including activated B cells, macrophages and dendritic cells. As costimulatory ligands, B7-1 which exists predominantly as dimer and the related protein B7-2, interact with the costimulatory receptors CD28 and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) expressed on T cells, and thus constitute one of the dominant pathways that regulate T cell activation and tolerance, cytokine production, and the generation of CTL. The B7/CD28/CTLA4 pathway has the ability to both positively and negatively regulate immune responses. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.Cancer ImmunotherapyCo-inhibitory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint Detection: AntibodiesImmune Checkpoint Detection: ELISA AntibodiesImmune Checkpoint Detection: FCM AntibodiesImmune Checkpoint Detection: IHC AntibodiesImmune Checkpoint Detection: WB AntibodiesImmune Checkpoint ProteinsImmune Checkpoint TargetsImmunotherapyTargeted Therapy |
Conjucates | FITC |
Others Formats | Unconjugated/Biotin/PE |
Antibody Types Available | 4 |
Immunogen | Recombinant Human CD80 / B7-1 Protein (TMPY-01063) |
Antigen Species | Human |
Biology Area | Cancer Drug Targets |
Stability & Storage | Store at 2°C-8°C for 12 months, do not freeze. Keep away from direct sunlight. |
Transport | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.